Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Estrella Immunopharma ( (ESLA) ) just unveiled an announcement.
On May 29, 2025, Estrella Immunopharma announced the initiation of dosing in the second cohort of its STARLIGHT-1 Phase I clinical trial for EB103, a CD19-redirected ARTEMIS® T-cell therapy aimed at treating Advanced B-Cell Non-Hodgkin’s Lymphomas. This milestone follows a successful first cohort with no dose-limiting toxicities, reflecting progress in Estrella’s mission to complete Phase I of the trial. The company aims to address limitations of traditional CAR-T therapies, particularly for high-risk patient groups, by evaluating EB103 at higher doses.
The most recent analyst rating on (ESLA) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Estrella Immunopharma stock, see the ESLA Stock Forecast page.
More about Estrella Immunopharma
Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing CD19 and CD22-targeted ARTEMIS® T-cell therapies for treating cancers and autoimmune diseases. The company’s lead product candidate, EB103, utilizes ARTEMIS® technology to target CD19, a protein expressed on most B-cell leukemias and lymphomas.
Average Trading Volume: 54,500
Technical Sentiment Signal: Sell
Current Market Cap: $35.8M
Learn more about ESLA stock on TipRanks’ Stock Analysis page.